Neuromity Therapeutics, Inc.
www.neuromity.comNeuromity is pioneering treatments for neurological disorders using deuterium-enabled chiral switching (DECS). Our lead program, NTY-184 (deuterium-stabilized S-bupropion), is being developed initially for major depressive disorder (MDD) as an NCE with new composition of matter IP via an expedited and derisked 505(b)(2) regulatory pathway.
Read more
Neuromity is pioneering treatments for neurological disorders using deuterium-enabled chiral switching (DECS). Our lead program, NTY-184 (deuterium-stabilized S-bupropion), is being developed initially for major depressive disorder (MDD) as an NCE with new composition of matter IP via an expedited and derisked 505(b)(2) regulatory pathway.
Read more
Country
State
Massachusetts
City (Headquarters)
Boston
Industry
Employees
1-10
Founded
2021
Social
Employees statistics
View all employeesPotential Decision Makers
Senior Vice President Translational Development and Founder
Email ****** @****.comPhone (***) ****-****President and Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Chief Operations Officer , Board , and Founder
Email ****** @****.comPhone (***) ****-****
Technologies
(5)
Reach decision makers at Neuromity Therapeutics, Inc.
Free credits every month!
Neuromity Therapeutics, Inc. FAQ
Boston, United States
Medical Equipment Manufacturing
